GCP
ODT

GSA Capital Partners’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

GSA Capital Partners’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-174,078
Closed -$235K – 1989
2021
Q4 		$235K Buy
174,078
+30,417
+21% +$71.9K 0.03% 1113
2021
Q3 		$418K Buy
143,661
+30,301
+27% +$101K 0.04% 807
2021
Q2 		$396K Buy
113,360
+74,450
+191% +$256K 0.04% 779
2021
Q1 		$133K Sell
38,910
-109,238
-74% -$2.06M 0.02% 976
2020
Q4 		$2.84M Buy
148,148
+134,490
+985% +$2.08M 0.47% 6
2020
Q3 		$183K Buy
+13,658
New +$387K 0.03% 1029

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

GSA Capital Partners's ODT Position: Q1 2022 in Review

GSA Capital Partners sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 174,078 shares — an estimated $235K sold.

GSA Capital Partners first reported a position in ODT in Q3 2020 and held it in 6 quarters. The position peaked at $2.84M in Q4 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • GSA Capital Partners reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 174,078 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $235K.
  • GSA Capital Partners first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
  • GSA Capital Partners's Odonate Therapeutics, Inc. Common Stock position peaked at $2.84M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.